Literature DB >> 18054795

Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.

David P Steensma1, Kathleen V Heptinstall, Victor M Johnson, Paul J Novotny, Jeff A Sloan, John K Camoriano, Joyce Niblack, John M Bennett, Ruben A Mesa.   

Abstract

Despite the clinical importance of health-related quality of life (QOL) in patients suffering from myelodysplastic syndromes (MDS), few data exist on the prevalence of key MDS-associated symptoms, or the correlation of those symptoms with specific disease features such as hemoglobin level. In order to better understand the burden of disease-associated symptoms in patients with MDS, we designed a 120-question Internet-based survey of QOL appropriate for patients with MDS, incorporating validated QOL measurement instruments and questions about specific therapies. The 359 survey respondents were typical of MDS patients in terms of demographics, blood counts, and disease subtype. Patients reported high levels of excessive fatigue and poor scores on QOL assessments such as the Functional Assessment of Cancer Therapy-Anemia (FACT-An) and the Brief Fatigue Inventory (BFI). Patients' debilitating fatigue correlated poorly with hemoglobin level, and fatigue was associated with significant impairment of both health-related QOL and ability to work or participate in desired activities. Within the limitations of self-reported data, these results provide a benchmark for future interventions to improve QOL in patients with MDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054795     DOI: 10.1016/j.leukres.2007.10.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  32 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Authors:  U Platzbecker; P Fenaux; L Adès; A Giagounidis; V Santini; A A van de Loosdrecht; D Bowen; T de Witte; G Garcia-Manero; E Hellström-Lindberg; U Germing; R Stauder; L Malcovati; Mikkael A Sekeres; David P Steensma; S Gloaguen
Journal:  Blood       Date:  2018-11-07       Impact factor: 22.113

Review 3.  Resuscitating a dying marrow: the role of hematopoietic growth factors.

Authors:  Aakriti Pandita; Sudipto Mukherjee
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

4.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Authors:  Michael R Savona; Luca Malcovati; Rami Komrokji; Ramon V Tiu; Tariq I Mughal; Attilio Orazi; Jean-Jacques Kiladjian; Eric Padron; Eric Solary; Raoul Tibes; Raphael Itzykson; Mario Cazzola; Ruben Mesa; Jaroslaw Maciejewski; Pierre Fenaux; Guillermo Garcia-Manero; Aaron Gerds; Guillermo Sanz; Charlotte M Niemeyer; Francisco Cervantes; Ulrich Germing; Nicholas C P Cross; Alan F List
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

Review 5.  Palliative and End-of-Life Care in Myelodysplastic Syndromes.

Authors:  Myles Nickolich; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

6.  Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients.

Authors:  Roberta Bruhn; Matthew S Karafin; Joan F Hilton; Zhanna Kaidarova; Bryan R Spencer; Lirong Qu; Edward L Snyder; Rebecca Olin; Edward L Murphy; Elizabeth St Lezin
Journal:  Qual Life Res       Date:  2020-05-07       Impact factor: 4.147

7.  Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.

Authors:  Francesca Palandri; Giulia Benevolo; Alessandra Iurlo; Elisabetta Abruzzese; Angelo M Carella; Chiara Paoli; Giuseppe A Palumbo; Massimiliano Bonifacio; Daniela Cilloni; Alessandro Andriani; Attilio Guarini; Diamante Turri; Elena Maria Elli; Antonietta Falcone; Barbara Anaclerico; Pellegrino Musto; Nicola Di Renzo; Mario Tiribelli; Renato Zambello; Caterina Spinosa; Alessandra Ricco; Letizia Raucci; Bruno Martino; Mario Annunziata; Silvia Pascale; Anna Marina Liberati; Giorgio La Nasa; Margherita Maffioli; Massimo Breccia; Novella Pugliese; Silvia Betti; Gianfranco Giglio; Antonietta Cappuccio; Luigi Reale
Journal:  Qual Life Res       Date:  2018-03-08       Impact factor: 4.147

Review 8.  Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

Authors:  Mikkael A Sekeres; David P Steensma
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

9.  Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine.

Authors:  Steven E McCormack; Erica D Warlick
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

10.  Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

Authors:  A El-Jawahri; H T Kim; D P Steensma; A M Cronin; R M Stone; C D Watts; Y-B Chen; C S Cutler; R J Soiffer; G A Abel
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.